Clinical trials
Completed Observational Peripheral Vascular Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
59 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 3 |
| 2003 | 4 |
| 2004 | 3 |
| 2006 | 3 |
| 2007 | 7 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 4 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 4 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 59 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 8 |
| AstraZeneca | 4 |
| Abbott Medical Devices | 2 |
| Boston Scientific Corporation | 2 |
| C. R. Bard | 2 |
| Canadian Medical and Surgical Knowledge Translation Research Group | 2 |
| Stanford University | 2 |
| Angiodynamics, Inc. | 1 |
| Brigham and Women's Hospital | 1 |
| Carmel Medical Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peripheral Vascular Diseases | 59 |
| Cardiovascular Diseases | 19 |
| Peripheral Arterial Disease | 18 |
| Coronary Disease | 12 |
| Diabetes Mellitus | 10 |
| Arterial Occlusive Diseases | 9 |
| Atherosclerosis | 9 |
| Heart Diseases | 7 |
| Stroke | 7 |
| Chronic Limb-Threatening Ischemia | 6 |
Trials
Showing 1 to 25 of 59. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.